Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.64 |
| ▸ | HTR7 | P34969 | 2/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.57 |
| ▸ | HTR2A | P28223 | 9/20 | 0.57 |
| ▸ | DRD2 | P14416 | 5/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | PGR | P06401 | 1/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.54 |
| ▸ | GOT1 | P17174 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | DRD1 | P21728 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7946844 | 0.99 | HTR1A (0.63) | HTR1AHTR7KCNH2HTR2ADRD2 | |
| Hydrochloric Acid SCHEMBL7412767 | 0.89 | HTR1A (0.62) | HTR1AHTR7KCNH2HTR2ADRD2 | |
| Hydrochloric Acid SCHEMBL4885489 | 0.86 | HTR1A (0.59) | HTR1AHTR7KCNH2HTR2ADRD2 | |
| SCHEMBL9752486 | 0.84 | HTR1A (0.63) | HTR1AHTR7KCNH2HTR2ADRD2 | |
| Hydrochloric Acid SCHEMBL4888338 | 0.84 | HTR1A (0.58) | HTR1AHTR7KCNH2HTR2ADRD2 | |
| SCHEMBL6404395 | 0.83 | HTR1A (0.64) | HTR1AHTR7KCNH2HTR2ADRD2 | |
| Hydrochloric Acid SCHEMBL9752511 | 0.82 | HTR1A (0.61) | HTR1AHTR7KCNH2HTR2ADRD2 | |
| SCHEMBL9371546 | 0.82 | HTR1A (0.61) | HTR1AHTR7KCNH2HTR2ADRD2 | |
| SCHEMBL4885467 | 0.81 | HTR1A (0.74) | HTR1AHTR7KCNH2HTR2ADRD2 | |
| SCHEMBL9366195 | 0.81 | HTR1A (0.59) | HTR1AHTR7KCNH2HTR2ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1633360-A1 | TREATMENT OF PSYCHOTIC AND DEPRESSIVE DISORDERS | Pfizer Products Incorporated (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1633361-A1 | ANXIETY TREATMENTS WITH ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1626722-A1 | METHOD FOR ENHANCING COGNITION USING ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| US-20050004137-A1 | Treatment of psychotic and depressive disorders | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| WO-2004100956-A1 | METHOD FOR ENHANCING COGNITION USING ZIPRASIDONE | PFIZER PRODUCTS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004100954-A1 | TREATMENT OF PSYCHOTIC AND DEPRESSIVE DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004100955-A1 | ANXIETY TREATMENTS WITH ZIPRASIDONE | PFIZER PRODUCTS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6245765-B1 | PSYCHOLOGICAL DISORDERS | PFIZER INC | 2001-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004137-A1 | Treatment of psychotic and depressive disorders | SNCA, NLN, INA | HTR1A 76/4885HTR7 238/4885KCNH2 1513/4885 |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | MC2R, NR3C1, CRH | HTR1A 79/4885HTR7 714/4885KCNH2 1329/4885 |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | DBH, RAP1A, GABRR1 | HTR1A 50/4885HTR7 290/4885KCNH2 2811/4885 |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | GABBR1, GABRR1, GABBR2 | HTR1A 80/4885HTR7 376/4885KCNH2 2492/4885 |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | NPSR1, AVPR1B, SLC39A3 | HTR1A 126/4885HTR7 610/4885KCNH2 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.